Drugs / ZX-4081
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05118841 | Jan 2022 → May 2023 | neoplasm | Nanjing Zenshine Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZX-4081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05118841 ↗ |
| Route | Oral | “Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle” NCT05118841 ↗ |